2013-03-21 10:02:33 - The need to increase the sensitivity and specificity of diagnostic tests is evolving the market to next-generation technologies, says RNCOS.
As per the new research report by RNCOS, “Infectious Disease Molecular Diagnostics Outlook 2015”, the market is gradually evolving to next-generation technologies for diagnosing infectious diseases through molecular diagnostics. Current trends in molecular diagnosis for infectious diseases are moving towards high-throughput, simple, array-type technologies, that will aim to generate extensive data regarding types of organisms present in a sample and the virulence factors/resistance determinants that influence the severity of disease. The ultimate purpose is to diagnose infectious diseases accurately and as a result get effective treatment.
Our study reveals that mass spectrometry is expected to grow stupendously. Mass spectrometry being a broad-based method offers the opportunity to integrate bacterial testing, fungal testing (apart from mycelial fungi) and mycobacteria into a one-step
process. Moreover, other promising approaches include miniaturized microfluidic systems, continuous-flow droplet-based PCR systems, which may revolutionize molecular diagnostics as they would use direct specimen testing and virtually eliminate the requirement of reagents. NGS sequencing is also emerging rapidly with its significant application especially in virology, to differentiate amongst multiple strains of organisms.
The report depicts an effective insight and prudent analysis of the current status and future positioning of the global infectious diseases molecular diagnostics market. It projects the future size of overall market for the period 2012-2015 and covers effective description of key drivers and trends that will propel the growth.
Moreover, the report illustrates the current performance of key infectious disease diagnostic segments (in terms of indications) to enumerate vertical sector demand. It analyzes the opportunity assessment for companies in the market in terms of technologies (e.g. PCR, RT-PCR, NASBA, etc.) and disease prevalence. Additionally, an in-depth insight into the FDA approved diagnostics products along with recent industry developments has been included in the report to provide a balanced outlook on the potentials of the global infectious diseases MDx sector.
For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM411.htm
Some of our related reports are:
- US Personalized Cancer Genome Sequencing Market (http://www.rncos.com/Report/IM453.htm)
- Brazil Healthcare - New Opportunities for Growth (http://www.rncos.com/Report/IM451.htm)
- US Non-Invasive Prenatal Diagnostics - Market Insight (http://www.rncos.com/Report/IM450.htm)
- US Cardiac Device Market Analysis (http://www.rncos.com/Report/IM441.htm)
- US Clinical Laboratory Testing Market Assessment (http://www.rncos.com/Report/IM442.htm)
Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm
RNCOS specializes in Industry intelligence and creative solutions for contemporary business segments. Our professionals analyze the industry and its various components, with a comprehensive study of the changing market behavior. Our accuracy and data precision proves beneficial in terms of pricing and time management that assist the intending consultants in meeting their objectives in a cost-effective and timely manner.